How does U.S. Healthtech compare with similar industries?

There are no additional sub-industries under this industry.

U.S. Healthtech Industry Analysis

Industry Valuation and Performance

Has the U.S. Healthtech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 10 Jun 2026	US$45.8b	US$14.4b	-US$757,471,326.00	29x	-60.5x	3.2x
Fri, 08 May 2026	US$48.3b	US$13.6b	-US$367,426,415.00	30.2x	-131.4x	3.5x
Sun, 05 Apr 2026	US$46.8b	US$13.6b	-US$416,162,415.00	32x	-112.5x	3.4x
Tue, 03 Mar 2026	US$49.5b	US$13.5b	-US$343,986,340.00	39.2x	-144x	3.7x
Thu, 29 Jan 2026	US$61.0b	US$13.6b	-US$102,102,340.00	47.5x	-597.7x	4.5x
Sat, 27 Dec 2025	US$64.4b	US$13.6b	-US$102,572,340.00	54.2x	-627.9x	4.7x
Mon, 24 Nov 2025	US$69.7b	US$13.6b	-US$117,958,271.00	52.4x	-591.1x	5.1x
Wed, 22 Oct 2025	US$79.7b	US$13.1b	-US$211,110,296.00	58.7x	-377.7x	6.1x
Fri, 19 Sep 2025	US$78.1b	US$13.2b	-US$266,647,296.00	58.6x	-292.9x	5.9x
Sun, 17 Aug 2025	US$77.2b	US$13.1b	-US$364,716,795.00	58.7x	-211.7x	5.9x
Tue, 15 Jul 2025	US$77.1b	US$13.2b	-US$1,382,394,447.00	55.4x	-55.8x	5.8x
Thu, 12 Jun 2025	US$78.9b	US$13.2b	-US$1,382,393,022.00	60.7x	-57.1x	6x
Sat, 10 May 2025	US$70.9b	US$13.1b	-US$1,463,322,959.00	56.7x	-48.4x	5.4x
Mon, 07 Apr 2025	US$62.9b	US$13.2b	-US$1,414,656,089.00	48.7x	-44.4x	4.8x
Wed, 05 Mar 2025	US$69.9b	US$13.1b	-US$1,568,031,514.00	63.2x	-44.6x	5.4x
Fri, 31 Jan 2025	US$71.5b	US$12.9b	-US$1,638,054,514.00	60.5x	-43.7x	5.6x
Sun, 29 Dec 2024	US$66.8b	US$12.9b	-US$1,636,315,514.00	55x	-40.8x	5.2x
Tue, 26 Nov 2024	US$64.3b	US$12.8b	-US$1,712,780,390.00	56x	-37.6x	5x
Thu, 24 Oct 2024	US$64.8b	US$13.5b	-US$3,126,871,151.00	53x	-20.7x	4.8x
Sat, 21 Sep 2024	US$66.1b	US$14.0b	-US$3,302,096,821.00	55.8x	-20x	4.7x
Mon, 19 Aug 2024	US$60.2b	US$13.9b	-US$3,360,989,829.00	56.7x	-17.9x	4.3x
Wed, 17 Jul 2024	US$58.1b	US$13.7b	-US$1,860,692,542.00	53x	-31.2x	4.2x
Fri, 14 Jun 2024	US$58.5b	US$13.7b	-US$1,889,788,216.00	47.3x	-31x	4.3x
Sun, 12 May 2024	US$56.3b	US$12.8b	-US$1,992,747,742.00	47x	-28.3x	4.4x
Tue, 09 Apr 2024	US$61.3b	US$12.7b	-US$1,619,729,105.00	51.6x	-37.8x	4.8x
Thu, 07 Mar 2024	US$63.3b	US$14.1b	-US$1,445,414,794.00	48.3x	-43.8x	4.5x
Sat, 03 Feb 2024	US$72.4b	US$18.3b	-US$5,780,316,752.00	58.7x	-12.5x	3.9x
Mon, 01 Jan 2024	US$72.5b	US$18.3b	-US$5,781,192,665.00	58.4x	-12.5x	4x
Wed, 29 Nov 2023	US$65.0b	US$18.2b	-US$5,807,346,665.00	52x	-11.2x	3.6x
Fri, 27 Oct 2023	US$65.4b	US$18.1b	-US$5,551,631,965.00	48.9x	-11.8x	3.6x
Sun, 24 Sep 2023	US$69.2b	US$18.0b	-US$5,514,972,389.00	50.4x	-12.6x	3.8x
Tue, 22 Aug 2023	US$69.7b	US$17.9b	-US$5,554,149,562.00	50.9x	-12.5x	3.9x
Thu, 20 Jul 2023	US$80.1b	US$17.7b	-US$8,580,548,318.00	61.8x	-9.3x	4.5x
Sat, 17 Jun 2023	US$76.1b	US$17.7b	-US$8,581,046,209.00	62.9x	-8.9x	4.3x

Current Industry PE

Investors are pessimistic on the American Health Care Technology industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The 3-year average PS ratio of 4.7x is higher than the industry's current PS ratio of 3.3x.

Past Earnings Growth

The earnings for companies in the Health Care Technology industry have improved over the last three years.
Meanwhile revenues for these companies have declined 6.7% per year.
This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.


US Market	-3.33%
Healthcare	5.05%
Healthtech	-6.65%
Healthtech	-6.65%

US Market

-3.33%

Healthcare

5.05%

Healthtech

-6.65%

Healthtech

-6.65%

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
EVH Evolent Health	US$4.72	19.2% +US$85.5m	-47.4%	PS0.3x
SOPH SOPHiA GENETICS	US$5.40	9.3% +US$33.0m	80.6%	PS4.8x
HCAT Health Catalyst	US$1.71	26.7% +US$26.6m	-58.7%	PS0.4x
HSTM HealthStream	US$26.00	3.1% +US$22.8m	-7.6%	PE38.1x
ITOC iTonic Holdings	US$0.40	38.8% +US$12.9m	-97.5%	PS88.5x

Inventurus Knowledge Solutions, Inc. entered into a definitive agreement to acquire TruBridge, Inc. (NasdaqGS:TBRG) from Pinetree Capital Ltd. (TSX:PNP), L6 Holdings Inc., Ocho Investments LLC and others for approximately $410 million.

Inventurus Knowledge Solutions, Inc. entered into a definitive agreement to acquire TruBridge, Inc. (NasdaqGS:TBRG) from Pinetree Capital Ltd. (TSX:PNP), L6 Holdings Inc., Ocho Investments LLC and others for approximately $410 million on April 23, 2026. Under the terms of the agreement, TruBridge shareholders will receive $26.25 in cash for each share of common stock. The transaction values TruBridge, Inc. with an enterprise value of approximately $565 million. IKS will finance the acquisition primarily through the incurrence of new indebtedness, including a term loan underwritten by Citibank, JPMorganChase, and Deutsche Bank, which is subject to satisfaction of customary conditions (including approval of the shareholders of IKS Health). Initial funding will be approximately $670 million through debt secured for a 5 year term. The leverage is expected at =3X EBITDA of combined entity. The initial interest cost is SOFR+275 bps sliding down to 17bps as leverage scales down. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Merger Sub will be merged with and into the TruBridge, Inc. (the “ Merger ”), with the TruBridge, Inc. continuing as the surviving corporation in the merger and becoming a wholly owned subsidiary of Inventurus Knowledge Solutions, Inc. Post acquisition, TruBridge, Inc. will be delisted. The Merger Agreement also provides that the TruBridge will be required to pay Inventurus Knowledge a termination fee of $12.3 million in certain circumstances, including if the TruBridge terminates the Merger Agreement to accept a Superior Proposal or if Inventurus Knowledge terminates the Merger Agreement because the Board of Directors of the TruBridge has effected a Change of Recommendation, or upon certain other triggering events. The Merger Agreement also provides that Inventurus Knowledge will be required to pay the TruBridge a reverse termination fee of $24.6 million if (i) either the TruBridge or Inventurus Knowledge terminates the Merger Agreement due to the failure to obtain the Requisite TopCo Approval or (ii) the Company terminates the Merger Agreement after (a) all mutual conditions to closing and all conditions to Inventurus Knowledge’s and Merger Sub’s obligations to effect the closing have been satisfied or waived (other than those conditions that by their nature are to be satisfied at the closing but subject to the ability for such conditions to be satisfied), (b) the TruBridge has confirmed in writing that it is ready, willing and able to consummate the closing, and (c) Inventurus Knowledge and Merger Sub fail to consummate the merger when required under the Merger Agreement, following a five (5) business day notice period. The consummation of the Merger is subject to various conditions, including, among others, customary conditions including (i) the adoption of the Merger Agreement by the Requisite Company Vote (as defined in the Merger Agreement), (ii) the statutory waiting period (and any extensions thereof) applicable to the consummation of the transactions contemplated by the Merger Agreement under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and, if applicable, any contractual waiting periods under any timing agreements in connection therewith, will have expired or been earlier terminated, (iii) no Governmental Entity (as defined in the Merger Agreement) will have enacted or enforced any law or order that is in effect and prevents the consummation of the transactions contemplated by the Merger Agreement, and (iv) the absence of a Company Material Adverse Effect (as defined in the Merger Agreement). The transaction is also subject to the requisite shareholder approvals. The acquisition has been approved by the Boards of Directors of IKS Health, IKS, and TruBridge, and is expected to close during the third calendar quarter of 2026, subject to the satisfaction of customary closing conditions. In connection with the transaction, TruBridge has entered into voting and support agreements with TruBridge’s largest shareholders, Pinetree Capital Ltd., L6 Holdings Inc. and Ocho Investments, LLC, who have agreed—subject to the terms of the agreements—to, among other things, vote the shares they control, representing in total approximately 27% of TruBridge’s outstanding shares of common stock, in favor of the transaction. The deal is expected to be PAT and EPS accretive in FY27. Solomon Partners Securities, LLC is acting as the exclusive financial advisor and fairness opinion provider to TruBridge, and Scott B. Crofton of Sullivan & Cromwell LLP, and Timothy W. Gregg of Maynard Nexsen PC, and Cyril Amarchand Mangaldas are acting as legal counsel. J.P. Morgan Securities LLC and Citigroup Global Markets India Private Limited are acting as financial advisors to IKS Health, and Mark D. Wood and Thomas F. Lamprecht of Katten Muchin Rosenman LLP and Shardul Amarchand Mangaldas & Co. are acting as legal counsel.

U.S. Healthtech Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

LifeMD: A Growing Healthcare Tech Stock, As Q1 Results Confirm Patient Demand

DOCS: Healthcare Moat And AI Investment Year Will Drive Future Engagement

Teladoc Health Faces Probe Into Possible Leadership Breaches Affecting Shareholders

New major risk - Shareholder dilution

Executive VP & CFO recently bought US$99k worth of stock

WAY: AI Automation And Buybacks Will Support Future Earnings Rerating

HCAT: Execution On Product Transition And Cost Cuts Will Shape 2026 Reset

Veeva Systems Inc. Updates Earnings Guidance for the Fiscal Year Ending January 31, 2027

Consensus EPS estimates increase by 15%

CERT: Biosimulation Partnerships And Model Informed Development Will Support Long Term Relevance

Price target decreased by 7.5% to US$36.83

Investor sentiment improves as stock rises 16%

EVH: Higher Margin Outlook And 2026 Earnings Guidance Will Support Future Upside

HSTM: AI Disruption Risks And Buybacks Will Shape Future Share Performance

Consensus EPS estimates fall by 12%, revenue upgraded

Inventurus Knowledge Solutions, Inc. entered into a definitive agreement to acquire TruBridge, Inc. (NasdaqGS:TBRG) from Pinetree Capital Ltd. (TSX:PNP), L6 Holdings Inc., Ocho Investments LLC and others for approximately $410 million.